share_log

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

トロント証券取引所、アンティーブ・セラピューティクス社、Cスイートからの見通し

PR Newswire ·  2023/08/21 15:23

TORONTO, Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.

The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit

Continue Reading
Antibe Therapeutics is working to replace outdated inflammation treatments with a safer alternative

About Antibe Therapeutics (TSX: ATE)

Antibe Therapeutics is a clinical-stage biotech company developing next-generation, safer medicines for pain and inflammation. The company's proprietary drug platform is designed to overcome the gastrointestinal ulcers and bleeding associated with NSAIDs, a class of drugs used by most North Americans and by billions of people globally.

CNW sponsored announcement. To learn more visit .

SOURCE Toronto Stock Exchange

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする